Literature DB >> 11708594

Updated recommendations for antimicrobial prophylaxis among asymptomatic pregnant women after exposure to Bacillus anthracis.

.   

Abstract

The antimicrobial of choice for initial prophylactic therapy among asymptomatic pregnant women exposed to Bacillus anthracis is ciprofloxacin, 500 mg twice a day for 60 days. In instances in which the specific B. anthracis strain has been shown to be penicillin-sensitive, prophylactic therapy with amoxicillin, 500 mg three times a day for 60 days, may be considered. Isolates of B. anthracis implicated in the current bioterrorist attacks are susceptible to penicillin in laboratory tests, but may contain penicillinase activity. Pencillins are not recommended for treatment of anthrax, where such penicillinase activity may decrease their effectiveness. However, penicillins are likely to be effective for preventing anthrax, a setting where relatively few organisms are present. Doxycycline should be used with caution in asymptomatic pregnant women and only when contraindications are indicated to the use of other appropriate antimicrobial drugs.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11708594

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  9 in total

1.  Birth defects and disabilities: a public health issue for the 21st century.

Authors:  Coleen A Boyle; José F Cordero
Journal:  Am J Public Health       Date:  2005-09-29       Impact factor: 9.308

2.  Public health approach to emerging infections among pregnant women.

Authors:  Sonja A Rasmussen; Edward B Hayes
Journal:  Am J Public Health       Date:  2005-09-29       Impact factor: 9.308

3.  Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax.

Authors:  David M Bell; Phyllis E Kozarsky; David S Stephens
Journal:  Emerg Infect Dis       Date:  2002-02       Impact factor: 6.883

4.  Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations.

Authors:  William O Cooper; Sonia Hernandez-Diaz; Patrick G Arbogast; Judith A Dudley; Shannon M Dyer; Patricia S Gideon; Kathleen S Hall; Lisa A Kaltenbach; Wayne A Ray
Journal:  Paediatr Perinat Epidemiol       Date:  2009-01       Impact factor: 3.980

Review 5.  Emerging infectious disease outbreaks: old lessons and new challenges for obstetrician-gynecologists.

Authors:  Denise J Jamieson; Jane E Ellis; Daniel B Jernigan; Tracee A Treadwell
Journal:  Am J Obstet Gynecol       Date:  2006-04-21       Impact factor: 8.661

Review 6.  Prophylaxis and treatment of pregnant women for emerging infections and bioterrorism emergencies.

Authors:  Joanne Cono; Janet D Cragan; Denise J Jamieson; Sonja A Rasmussen
Journal:  Emerg Infect Dis       Date:  2006-11       Impact factor: 6.883

Review 7.  Emerging infections and pregnancy: West Nile virus, monkeypox, severe acute respiratory syndrome, and bioterrorism.

Authors:  Denise J Jamieson; Daniel B Jernigan; Jane E Ellis; Tracee A Treadwell
Journal:  Clin Perinatol       Date:  2005-09       Impact factor: 2.642

8.  Opening a bacillus anthracis-containing envelope, Capitol Hill, Washington, D.C.: the public health response.

Authors:  Vincent P Hsu; Susan L Lukacs; Thomas Handzel; James Hayslett; Scott Harper; Thomas Hales; Vera A Semenova; Sandra Romero-Steiner; Cheryl Elie; Conrad P Quinn; Rima Khabbaz; Ali S Khan; Gregory Martin; John Eisold; Anne Schuchat; Rana A Hajjeh
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

9.  Public health in the time of bioterrorism.

Authors:  Bradley A Perkins; Tanja Popovic; Kevin Yeskey
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.